Skip to content

Study · Non-randomized trial · n = 17 · 2004

12 results

Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.

Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 May 2004Cited by 40 (Europe PMC)

PMID15126555 (opens in a new tab)DOI10.1210/jc.2003-031799 (opens in a new tab)PepBankPUB-15126555
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day continuous subcutaneous GHRP‑2 infusion raised pulsatile GH secretion more than 3-fold on day 1 and more than 1.8-fold on days 14 and 30 versus saline.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised pulsatile growth hormone release compared with saline.

    Peptide
    GHRP-2
    Outcome
    IncreasePulsatile GH secretion during 30-day GHRP-2 infusion
    Study

    n = 17

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Measurements

    Pulsatile GH secretion increase
    > 3 fold
    day 1
    Pulsatile GH secretion increase
    > 1.8 fold
    day 14 and 30

    Source sentences

    Summary
    stimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold on d 1 and more than 1.8-fold on d 14 and 30 (each P < 0.001 vs. saline)
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day continuous subcutaneous GHRP‑2 infusion raised rhythmic GH secretion versus saline.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised the daily rhythm of growth hormone release compared with saline.

    Peptide
    GHRP-2
    Outcome
    IncreaseRhythmic GH secretion during 30-day GHRP-2 infusion
    Study

    n = 17

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Source sentences

    Summary
    stimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold on d 1 and more than 1.8-fold on d 14 and 30 (each P < 0.001 vs. saline)
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day continuous subcutaneous GHRP‑2 infusion raised entropic GH secretion versus saline.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised an entropy measure of growth hormone release compared with saline.

    Peptide
    GHRP-2
    Outcome
    IncreaseEntropic GH secretion during 30-day GHRP-2 infusion
    Study

    n = 17

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Source sentences

    Summary
    stimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold on d 1 and more than 1.8-fold on d 14 and 30 (each P < 0.001 vs. saline)
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day GHRP‑2 infusion elevated IGF-I to a stable plateau on days 1, 14 and 30 versus baseline.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised IGF-I and kept it steady, compared with baseline.

    Peptide
    GHRP-2
    Outcome
    IncreaseIGF-I during 30-day GHRP-2 infusion
    Study

    n = 17

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Source sentences

    Summary
    elevated IGF-I to a stable plateau on d 1, 14, and 30 (P < 0.025 vs. baseline)
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day GHRP‑2 infusion increased IGFBP-3 on day 14 and/or 30.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised IGFBP-3, a protein that carries IGF-I in the blood.

    Peptide
    GHRP-2
    Outcome
    IncreaseIGFBP-3 during 30-day GHRP-2 infusion
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Source sentences

    Summary
    increased IGFBP-3 (P < 0.01) and IGFBP-5 (P < 0.025) on d 14 and/or 30
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy older adults, 30-day GHRP‑2 infusion increased IGFBP-5 on day 14 and/or 30.

    In plain wordsIn healthy older adults, a 30-day GHRP‑2 infusion raised IGFBP-5, a protein that binds IGF-I in the blood.

    Peptide
    GHRP-2
    Outcome
    IncreaseIGFBP-5 during 30-day GHRP-2 infusion
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 30 daysAs given in this study (human).

    Source sentences

    Summary
    increased IGFBP-3 (P < 0.01) and IGFBP-5 (P < 0.025) on d 14 and/or 30
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy older adults, GHRP‑2 with GHRH stimulated GH secretion more than GHRH alone.

    In plain wordsIn healthy older adults, adding GHRP‑2 to GHRH raised growth hormone release more than GHRH alone.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion with GHRP-2 plus GHRH versus GHRH alone
    Study

    n = 11

    Comparator
    GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the entire cohort (n = 11), GHRP-2/GHRH (1/10) stimulated GH secretion more than either GHRP-2 (1; P = 0.021) or GHRH (10; P = 0.012).
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy older adults, a 24-h infusion of GHRP‑2 combined with GHRH drove GH secretion more than GHRH alone.

    In plain wordsIn healthy older adults, adding GHRP‑2 to GHRH for 24 hours raised growth hormone release more than GHRH alone.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion during 24-h GHRP-2 plus GHRH infusion versus GHRH alone
    Study

    n: not reported in source

    Comparator
    GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg.h · subcutaneous · 24 hAs given in this study (human).

    Source sentences

    Summary
    The 24-h infusion of GHRP-2 (1) combined with GHRH (3 or 10) in men and with GHRH (10) in women drove GH secretion more than GHRH alone (P <or= 0.024).

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 09HumanNot a test of GHRP-2 aloneNon-randomized trialMechanism

    In healthy volunteers, the acute GH response to GHRP‑2 and GHRH together was 3-fold greater in young than in older people.

    In plain wordsIn healthy volunteers, the extra growth hormone release from giving GHRP‑2 and GHRH together was 3-fold smaller in older people than in young people.

    Peptide
    GHRP-2
    Outcome
    DecreaseAcute GHRP-2 and GHRH synergy, young versus older
    Study

    n = 33

    Comparator
    Young volunteers
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Acute two-peptide synergy was 3-fold greater in young (n = 16) than older volunteers (n = 17; P < 0.025)

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 10HumanNot a test of GHRP-2 aloneNon-randomized trialEfficacy outcome

    In healthy older adults, GHRP‑2 with GHRH stimulated GH secretion more than GHRP‑2 alone.

    In plain wordsIn healthy older adults, GHRP‑2 and GHRH together raised growth hormone release more than GHRP‑2 alone.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion with GHRP-2 plus GHRH versus GHRP-2 alone
    Study

    n = 11

    Comparator
    GHRP-2 alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In the entire cohort (n = 11), GHRP-2/GHRH (1/10) stimulated GH secretion more than either GHRP-2 (1; P = 0.021) or GHRH (10; P = 0.012).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 11HumanNot a test of GHRP-2 aloneNon-randomized trialMechanism

    In elderly volunteers, the acute GH response to GHRP‑2 and GHRH together was 2.3-fold higher in women than in men.

    In plain wordsIn older adults, the growth hormone release from GHRP‑2 and GHRH together was 2.3-fold higher in women than in men.

    Peptide
    GHRP-2
    Outcome
    IncreaseAcute GHRP-2 and GHRH synergy, women versus men
    Study

    n: not reported in source

    Comparator
    Elderly men
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Acute two-peptide synergy was 3-fold greater in young (n = 16) than older volunteers (n = 17; P < 0.025) and was 2.3-fold higher in elderly women than men (P < 0.025).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 12HumanNot a test of GHRP-2 aloneNon-randomized trialSafety outcome

    In healthy older adults given GHRP‑2, GHRH or both, safety screening tests remained normal.

    In plain wordsIn healthy older adults given GHRP‑2, GHRH or both, safety screening tests stayed normal.

    Peptide
    GHRP-2
    Outcome
    No significant changeSafety screening tests
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Safety screening tests remained normal.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.